Bibiliography

  1. Adiletto C, Wang S, Gordon N, et al. Between lot variation of the BGM Galectin-3™ assay evaluated at a CLIA laboratory. (Presented at the American Association for Clinical Chemistry Annual Meeting, 2010, Anaheim, CA).
  2. Adiletto C, Wang S, Gordon N, et al. Stability of galectin-3 in serum and plasma at various temperatures as measured with the BGM Galectin-3™ assay. (Presented at the American Association for Clinical Chemistry Annual Meeting, 2010, Anaheim, CA).
  3. Almkvist J, Karlsson A. Galectins as inflammatory mediators, Glycoconj J. 2004;19:575-81.
  4. Barboni EA, Bawumia S, Henrick K, et al. Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding Glycobiology. 2000;10:1201-8.
  5. Barondes SH, Castronovo V, et al. A family of animal beta-galactoside-binding lectins Cell. 1994;76:597-8.
  6. Braunwald E. Biomarkers in heart failure N Engl J Med. 2008;20:2148-59.
  7. Calvier L, Martin-Fernãndez B, Lahera V, et al. Galectin-3 is a potential mediator of aldosterone effects in vascular remodeling. (Presented at the European Society of Cardiology Heart Failure Congress May 2011, Gothenburg, Sweden).
  8. Christenson RH, Duh S-H, Wu AH, et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure Clin Biochem. 2010;43:683 - 90.
  9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling J Am Coll Cardiol. 2000;35:569-82.
  10. Cooper DN. Galectinomics: Finding themes in complexity Biochem Biophys Acta. 2002;1572:209-31.
  11. de Boer RA, Lok D, Hillege JL, et al. Clinical and prognostic value of galectin-3, a novel fibrosis-associated biomarker. Relation with clinical and biochemical correlates of heart failure J Am Coll Cardiol. 2010;55:A26. (Presented at the American College of Cardiology Annual Scientific Session, 2010, Atlanta, GA).
  12. de Boer RA, Lok D, Jaarsma T, et al. Predictive Value of Plasma Galectin-3 levels in Heart Failure with Reduced and Preserved Ejection Fraction, Ann Med. 2011;43(1):60-8.
  13. de Boer RA, Van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, Van Gilst WH, Hillege HL, Bakker SJL, Van Der Harst P.  The fibrosis marker galectin-3 and outcome in the general population: data from PREVEND. J Intern Med. 2011 Oct 25. [Epub ahead of print].
  14. de Boer RA, Van Veldhuisen DJ, Gansevoort RT, Muller Kobold A, Sillje HHW, Van Gilst WH, Hillege HL, Bakker SJL, Van Der Harst P. Galectin-3, cardiovascular risk factors, and outcome in the general population. (Presented at the European Society of Cardiology Congress Annual Meeting, 2011, Paris, France).
  15. de Boer RA., van Veldhuisen DJ, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P. Changes in Galectin-3 Levels Over Time Predict Mortality and Morbidity in Chronic HF. (Presented at the Heart Failure Society of America Annual Scientific Meeting, 2011, Boston, MA).
  16. de Boer, RA, van Veldhuisen DJ, DeFilippi C, Muntendam P, Adourian A, Guo Y, Januzzi J.  Plasma Galectin-3 is Associated with Near-Term Rehospitalization in Heart Failure: A Meta-Analysis. (Presented at the Heart Failure Society of America Annual Scientific Meeting, 2011, Boston, MA).
  17. de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression Eur J Heart Fail. 2009;11:811-17.
  18. de Boer RA., Wanner C., Blouin K., and Drechsler C. Galectin-3 and Outcomes in Patients with End-Stage Renal Disease.  Data from the German Diabetes and Dialysis Study.  (Presented at the American Heart Association Scientific Meeting, 2011, Orlando, FL).
  19. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure Curr Heart Fail Rep. 2010;7:1-8.
  20. de Couto G, Ouzounian M, Liu PP. Early Detection of Myocardial Dysfunction and Heart Failure. Nat Rev Cardiol. 2010 Jun;7(6):334-44.
  21. deFilippi C, Christenson R, Shah R, et al. Clinical validation of a novel assay for galectin-3 for risk assessment in acutely destabilized heart failure J Card Fail. 2009;15:S9. (Presented at the Heart Failure Society of America Annual Scientific Meeting, 2009, Boston, MA).
  22. deFilippi CR, Felker GM. Galectin-3 in heart failure-linking fibrosis, remodeling, and progression US Cardiology. 2010;7:67-70.
  23. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story Biochim Biophys Acta. 2006;1760:616-35.
  24. Felker GM, Fiuzat M, Shaw LK, et al. Prognostic value of Galectin-3 in chronic heart failure: results from the HF-ACTION study (Presented at the European Society of Cardiology Congress, 2010, Stockholm, Sweden).
  25. Fermann GJ., Collins SP, Lindsell CJ, et al. Galectin-3 levels correlate with increased creatinine, BNP and Adverse 30 Day Event Rates in Patients with Acute Heart Failure Syndrome (Oral presentation at the Society for Academic Emergency Medicine May 2011, Boston, MA).
  26. Galectin-3 assay; Product Insert (US); BG Medicine, Inc., March 2011.
  27. Gopal DM., Kommineni M, Ayalon N., et al. Plasma Galectin-3 in Patients with Heart Failure: Relationship to Clinical Status, Pathophysiology of Heart Failure, and Renal Function. (Presented at the Heart Failure Society of America Annual Scientific Meeting, 2011, Boston, MA).
  28. Grandin E, Cannon C, Jarolim P, et al., Galectin-3 and the development of heart failure after acute coronary syndrome: A pilot experience from PROVE IT-TIMI 22. J Am Coll Cardiol 2011;57:69.
  29. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22.  Clin Chem 2011 Nov 22 (Epub ahead of print).
  30. Gruson D. Circulating levels of galectin-3, a marker of cardiac remodeling, in congestive heart failure (Presented at the Belgium Society of Cardiology Meeting Feb 2011, Brussels, Belgium.
  31. Gruson D., Ahn SA., Ketelslegers JM., and Rousseau MF.  Galectin-3 as a New Remodeling Marker in Heart Failure: Comparison to other Neurohumoral Biomarkers. (Presented at the Heart Failure Society of America Annual Scientific Meeting, 2011, Boston, MA).
  32. Gullestad L, Ueland T, Nymo S, Kjekshus J, Hulthe J, Muntendam P, Adourian A, McMurray J, Wikstrand J, Aukrust P. Galectin-3 predicts response to statin therapy in chronic heart failure. (Presented at the European Society of Cardiology Congress Annual Meeting, 2011, Paris, France).
  33. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am J Pathol 2008;172:288-98.
  34. Henderson NC, Mackinnon AC, Garnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis Proc Natl Acad Sci. 2006;103:5060-65.
  35. Henderson NC, Sethi T. The regulation of inflammation by galectin-3 Immunol Rev. 2009;230:160-71.
  36. Kasper M, Hughes RC. Immunocytochemical evidence for a modulation of galectin-3 (mac2), a carbohydrate binding protein, in pulmonary fibrosis J Pathol. 1996; 179:309-16.
  37. Kim H, Lee J, Hyun JW, et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues Cell Biol Int. 2007;31:655-62.
  38. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One. 2011 Apr 8;6(4):e18683.
  39. Lainscak M., Coletta A., Sherwi N. Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1. Eur J Heart Fail. 2010 Feb;12(2):193-6.
  40. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction Int J Cardiol. 2008;130:147-58.
  41. Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients Clin Chim Acta. 2009;409:96-9.
  42. Liu H, D’Ambrosio M, Liao T, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Am J Physiol Heart Circ Physiol. 2009;296:H404-12.
  43. Lok D, van der Meer P, de la Porte PB, et al. Plasma galectin-3 levels predict left ventricular remodeling determined by sequential echocardiography: results from the Deventer-Alkmaar heart failure study J Am Coll Cardiol. 2010;55:A17. (Presented at the American College of Cardiology Annual Scientific Session, 2010, Atlanta, GA).
  44. Lok DJA, van der Meer P, de la Porte PWB, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol. 2010;99:323-8.
  45. Lok D, van der Meer P, de La Porte PM, et al. Galectin-3, a novel marker of macrophage activity, predicts outcome in patients with stable chronic heart failure.  J Am Coll Cardiol. 2007;49:98A.
  46. Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex Eur J Biochem.  1999;264:569-76.
  47. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices J Heart Lung Transplant. 2008;27:589-96.
  48. Muntendam P, Adourian A, Christenson R. Reference interval for plasma galectin-3 in healthy subjects age 55 years and older Clin Chem. 2009;55:B72. (Presented at the American Association for Clinical Chemistry Annual Meeting, 2009, Chicago, IL).
  49. Nishi Y, Sano H, Kawashima T, et al. Role of galectin-3 in human pulmonary fibrosis Allergol Int. 2007;56:57-65.
  50. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3 Glycoconj J. 2004;19:527-35.
  51. Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in ventricular remodelling Lancet. 2006;367:356-67.
  52. Psarras S, Mavroidis M, Sanoudou D, Davos CH, Xanthou G, Varela AE, Panoutsakopoulou V, Capetanaki Y. Regulation of adverse remodelling by osteopontin in a genetic heart failure model. Eur Heart J. 2011 Apr 26.
  53. Rossignol P, Fay R, Iraqi W, et al. Galectin-3 and PIIINP are associated with cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dyschrony. Insights from the CARE-HF study. (Presented at the European Society of Cardiology Congress, 2010, Stockholm, Sweden).
  54. Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages J Clin Invest. 2003;112:389-97.
  55. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies J Pathol.1999;187:481-9.
  56. Sathisha UV, Jayaram S, Nayaka MAH, Inhibition of galectin-3mediated cellular interactions by pectic polysaccharides from dietary sources Glycoconj J (2007) 24:497–507.
  57. Sato S, Rabinovich GA. Galectins as danger signals in host-pathogen and host-tumor interactions: new members of the growing group of “alarmins”? Galectins; John Wiley & Sons; Eds: Klyosov AA, Zbigniew JW, Platt D. 2008;DOI:10.1002/9780470378076.ch7.
  58. Seetharaman J, Kanigsberg A, Slaaby R, et al. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution J Biol Chem. 1998;273:3047-52.
  59. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail. 2010 Aug;12(8):826-32.
  60. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acute heart failure J Am Coll Cardiol. 2010;55:A34.  (Presented at the American College of Cardiology Annual Scientific Session, 2010, Atlanta, GA).
  61. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation. 2004;110:3121-28.
  62. Sharma U, Rhaleb NE, Pokharel S, et al. Novel anti-inflammatory mechanisms of N-acetyl-ser-asp-lys-pro in hypertension-induced target organ damage Am J Physiol Heart Circ Physiol. 2008;294:H1226-32.
  63. Sherwi NS, Lukaschuk EL, Zhang J, et al. Does the severity of LV dysfunction or the extent of myocardial scar explain elevations in  plasma galectin-3 in patients with heart failure Eur J Heart Fail Suppl. 2010;9:S18 (Presented at the European Society of Cardiology Heart Failure Congress, 2010, Berlin, Germany).
  64. Smith A, Wu AH, Abel G, et al. Analytical performance of an optimized ELISA for galectin-3 Clin Chem. 2009;55:B69. (Presented at the American Association for Clinical Chemistry Annual Meeting, 2009, Chicago, IL).
  65. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of Plasma Galectin-3 Levels in Systolic Heart Failure to Predict Renal Insufficiency and Survival. Am J Cardiol. 2011 May 18.
  66. Ueland T, Aukrust P, Broch K, Aakhus S, Skårdal R, Muntendam P, Gullestad L. Galectin-3 in heart failure: high levels are associated with all-cause mortality.  IJCA-13561 In press.
  67. van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol. 2006; 48:1217-24.
  68. van Veldhuisen DJ, Lok DJA, Damman K, et al. Clinical and prognostic value of galectin-3, a novel fibrosis-associated biomarker, in patient with chronic heart failure J Card Fail. 2009;15:814.
  69. Wang S, Shepherd K, Gordon N. Evaluation of the BGM Galectin-3™ assay on the Dynex Technologies DSX™ 4-plate system, an automated microplate processing system (Presented at the American Association for Clinical Chemistry Annual Meeting, 2010, Anaheim, CA).
  70. Yanavitski M, Givertz MM. Novel Biomarkers in Acute Heart Failure; Curr Heart Fail Rep. 2011 Jun 17.
  71. Yang RY, Rabinovich GA, Liu FT. Galectins: Structure, function and therapeutic potential Expert Rev Mol Med. 2008;13:e17-e39.
  72. Yu L, Ruifrok WP, Sillje HHW, Bos E, Van Goor H, Van Veldhuisen DJ, Van Gilst WH,  de Boer RA Genetic disruption of galectin-3 prevents adverse cardiac remodeling. (Presented at the European Society of Cardiology Congress Annual Meeting, 2011, Paris, France).
  73. Yu L, Ruifrok WP, Sillje HHW, Bos E, Van Goor H, Van Veldhuisen DJ, Van Gilst WH,  de Boer RA. Pharmacological inhibition of galectin-3 attenuates adverse cardiac remodeling and heart failure. (Presented at the European Society of Cardiology Congress Annual Meeting, 2011, Paris, France).
  74. Zile MR, Johnson RH, DeSantis SM, et al. Plasma galectin-3 levels in patients with structural and clinical manifestations of hypertensive heart disease: relationship to determinants of matrix composition.  (Presented at the American Heart Association Scientific Sessions, 2010, Chicago, IL).